[go: up one dir, main page]

CL2015002723A1 - Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23 - Google Patents

Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23

Info

Publication number
CL2015002723A1
CL2015002723A1 CL2015002723A CL2015002723A CL2015002723A1 CL 2015002723 A1 CL2015002723 A1 CL 2015002723A1 CL 2015002723 A CL2015002723 A CL 2015002723A CL 2015002723 A CL2015002723 A CL 2015002723A CL 2015002723 A1 CL2015002723 A1 CL 2015002723A1
Authority
CL
Chile
Prior art keywords
antibody
methods
treat psoriasis
psoriasis
treat
Prior art date
Application number
CL2015002723A
Other languages
English (en)
Inventor
Wayne Tsuji
John P Gibbs
Wei-Jian Pan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002723(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2015002723A1 publication Critical patent/CL2015002723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)

Abstract

METODO PARA TRATAR PSORIASIS QUE COMPRENDE USAR ANTICUERPO ANTI-IL-23
CL2015002723A 2013-03-15 2015-09-15 Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23 CL2015002723A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002723A1 true CL2015002723A1 (es) 2016-03-28

Family

ID=50336511

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002723A CL2015002723A1 (es) 2013-03-15 2015-09-15 Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23

Country Status (17)

Country Link
US (3) US20160060337A1 (es)
EP (2) EP2968488A1 (es)
JP (4) JP2016517408A (es)
KR (1) KR20150128858A (es)
CN (1) CN105209064A (es)
AP (1) AP2015008803A0 (es)
AU (3) AU2014238148A1 (es)
CA (1) CA2906382A1 (es)
CL (1) CL2015002723A1 (es)
CR (1) CR20150572A (es)
EA (1) EA201591581A1 (es)
HK (1) HK1219425A1 (es)
IL (2) IL241342A0 (es)
PH (2) PH12015502129A1 (es)
SG (2) SG10201804954UA (es)
TN (1) TN2015000403A1 (es)
WO (1) WO2014149425A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2635601T3 (en) 2010-11-04 2016-09-19 Boehringer Ingelheim Int Anti-IL-23 antibodies
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
CN107109456B (zh) 2014-09-03 2021-02-23 博灵格英格尔海姆国际股份公司 靶向IL-23A和TNF-α的化合物及其用途
EA201791734A1 (ru) * 2015-02-04 2018-01-31 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения воспалительных заболеваний
MA44510A (fr) * 2016-03-29 2021-03-31 Janssen Biotech Inc Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
JP6728392B2 (ja) * 2016-04-15 2020-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
US20200025776A1 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
BR112021008582A8 (pt) * 2018-11-05 2023-02-07 Merck Sharp & Dohme Regime de dosagem de anticorpo anti-tigit para tratamento de câncer
WO2020188466A1 (en) * 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CO4810232A1 (es) 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
CN101296944A (zh) 2005-08-31 2008-10-29 先灵公司 工程改造的抗il-23抗体
AU2006330410A1 (en) * 2005-12-28 2007-07-05 Centocor, Inc. Markers and methods for assessing and treating psoriasis and related disorders
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
AU2008218968B2 (en) 2007-02-23 2013-10-17 Merck Sharp & Dohme Llc Engineered anti-IL-23p19 antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US8178092B2 (en) * 2008-03-18 2012-05-15 Abbott Laboratories Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
WO2010002776A2 (en) 2008-06-30 2010-01-07 Black & Decker Inc. Cord protector for power tools
AU2009288419B2 (en) 2008-08-27 2015-08-06 Merck Sharp & Dohme Llc Lyophilized formulatons of engineered anti-IL-23p19 antibodies
JP2012522749A (ja) 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗ｉｌ−２３免疫グロブリン
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
IN2012DN01965A (es) * 2009-09-14 2015-08-21 Abbvie Deutschland
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
NZ601125A (en) 2010-01-15 2014-08-29 Kirin Amgen Inc Antibody formulation and therapeutic regimens
CN103108886B (zh) 2010-07-20 2016-08-24 赛法隆澳大利亚控股有限公司 抗il-23杂二聚体特异性抗体
CA2813208A1 (en) * 2010-10-06 2012-04-12 Abbvie Inc. Methods for treating psoriasis
PL2625199T3 (pl) * 2010-10-08 2018-04-30 Novartis Ag Sposoby leczenia łuszczycy z zastosowaniem antagonistów il-17
DK2635601T3 (en) 2010-11-04 2016-09-19 Boehringer Ingelheim Int Anti-IL-23 antibodies

Also Published As

Publication number Publication date
CA2906382A1 (en) 2014-09-25
EP3689369A1 (en) 2020-08-05
EP2968488A1 (en) 2016-01-20
JP2021102644A (ja) 2021-07-15
IL241342A0 (en) 2015-11-30
IL275093A (en) 2020-07-30
AU2014238148A1 (en) 2015-10-08
EA201591581A1 (ru) 2016-01-29
PH12019502700A1 (en) 2020-12-07
CN105209064A (zh) 2015-12-30
JP2016517408A (ja) 2016-06-16
JP2020063237A (ja) 2020-04-23
AU2019200206A1 (en) 2019-01-31
KR20150128858A (ko) 2015-11-18
AU2020270495A1 (en) 2020-12-17
AP2015008803A0 (en) 2015-10-31
US20200277368A1 (en) 2020-09-03
JP2023011815A (ja) 2023-01-24
WO2014149425A1 (en) 2014-09-25
PH12015502129A1 (en) 2016-01-25
HK1219425A1 (zh) 2017-04-07
CR20150572A (es) 2016-04-25
SG11201507482UA (en) 2015-10-29
TN2015000403A1 (en) 2017-01-03
SG10201804954UA (en) 2018-07-30
US20160060337A1 (en) 2016-03-03
US20220135668A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
CL2015002723A1 (es) Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23
BR112015030351A2 (pt) método e aparelho para realização de transações locais
BR112015020236A2 (pt) método e aparelho para comunicação focalizada de dados
CL2017002728A1 (es) Método para el tratamiento de cáncer
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
CL2015001929A1 (es) Sistema y método optico para seleccionar semillas
AR091700A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
CL2015003049A1 (es) Variantes de pertuzumab y su evaluación
ES2813450T8 (es) Compuestos y métodos para tratar un trastorno epiléptico
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
EP3022216C0 (en) IMPROVED PROCESS FOR ORGANIC SOLVENT TREATMENT OF LIGNOCELLULOSIC BIOMASS
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112016014327A2 (pt) método e aparelho para predição de tabela de paleta
BR112013028187A2 (pt) processo para produzir olefinas
BR112014000351A2 (pt) “método para tratamento prévio de biomassa lignocelulósica”
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
BR112013031968A2 (pt) método e aparelho para testes magnéticos
BR112013029484A2 (pt) método para o tratamento de tumores sólidos avançados
UY34708A (es) Metodo para producir glicósidos de esteviol
BR112013024363A2 (pt) método, e aparelho
BR112013032218A2 (pt) método para coprodução de hidrocarbonetos
BR112013023227A2 (pt) método para tratar perda de circulação, e material de circulação perdida de gelificação (lcm)
MX2015015148A (es) Proceso para la preparacion de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos en una cascada de reactores.
BR112015023511A2 (pt) tensor
BR112015028700A2 (pt) sistema e método para fornecer um serviço de produção de conteúdo em 4d e aparelho de produção de conteúdo